Chen Zhong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Chen Zhong has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Guojuan Wang
Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, China
1 shared publicationMin Guo
Jiangxi University of Chinese Medicine, Nanchang, China
1 shared publicationNaicheng Zhu
Jiangxi University of Chinese Medicine, Nanchang, China
1 shared publication- Nanxin Li
Analysis Group, Inc., Boston, MA
1 shared publication - Wenyan Yu
Research Center for Differentiation and Development of TCM Basic Theory, Jiangxi Key Laboratory of Etiology and Biology of TCM, Discipline of Chinese and Western Integrative Medicine, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, P. R. China
1 shared publication Xiudan Chen
Jiangxi University of Chinese Medicine, Nanchang, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2024
- Published by SAGE Publications in Cancer Control
- Vol. 31
The Role of Tumor Stem Cells in Colorectal Cancer Drug Resistance
Background: Colorectal cancer is a major cause of mortality among the prevalent malignant tumors of the gastrointestinal tract. Although chemotherapy is a standard treatment for colorectal cancer, its efficacy is limited by chemoresistance. Recent studies have investigated targeting tumor stem cells as a potential new therapeutic approach for addressing chemoresistance in colorectal cancer. Colorectal cancer frequently relapses, with tumor stem cells often representing one of the leading causes of treatment failure. Purpose: Understanding drug resistance in colorectal cancer stem cells is crucial for improving treatment outcomes. By focusing on developing targeted therapies that specifically address drug resistance in colorectal cancer stem cells, there is potential to make significant advancements in the treatment of colorectal cancer.This approach may lead to more effective and lasting outcomes in patients battling colorectal cancer. Research Design: In this review, a comprehensive overview of recent research on colorectal cancer stem cell treatment resistance is presented.Results: Elucidating the key underlying mechanisms. This review also highlights the potential benefits of targeted therapies in overcoming colorectal cancer resistance to treatment. Conclusions: CCSCs are key players in drug resistance of CRC, indicating their potential as targets for effective therapy. Elucidating their role in this process could aid in discovering tailored treatment strategies.The significance of signaling pathways, TME, and miRNA in regulating drug resistance in CCSCs is been highlighted.
- 1 January 2024
- Published by SAGE Publications in Cancer Control
- Vol. 31
Open AccessThe Role of Tumor Stem Cells in Colorectal Cancer Drug Resistance
Background: Colorectal cancer is a major cause of mortality among the prevalent malignant tumors of the gastrointestinal tract. Although chemotherapy is a standard treatment for colorectal cancer, its efficacy is limited by chemoresistance. Recent studies have investigated targeting tumor stem cells as a potential new therapeutic approach for addressing chemoresistance in colorectal cancer. Colorectal cancer frequently relapses, with tumor stem cells often representing one of the leading causes of treatment failure. Purpose: Understanding drug resistance in colorectal cancer stem cells is crucial for improving treatment outcomes. By focusing on developing targeted therapies that specifically address drug resistance in colorectal cancer stem cells, there is potential to make significant advancements in the treatment of colorectal cancer.This approach may lead to more effective and lasting outcomes in patients battling colorectal cancer. Research Design: In this review, a comprehensive overview of recent research on colorectal cancer stem cell treatment resistance is presented.Results: Elucidating the key underlying mechanisms. This review also highlights the potential benefits of targeted therapies in overcoming colorectal cancer resistance to treatment. Conclusions: CCSCs are key players in drug resistance of CRC, indicating their potential as targets for effective therapy. Elucidating their role in this process could aid in discovering tailored treatment strategies.The significance of signaling pathways, TME, and miRNA in regulating drug resistance in CCSCs is been highlighted.